Research
Shorter Cycle Maintains Efficacy of Colorectal Cancer Regimen
The Brief
- A phase III trial from Japan, PRABITAS, tested a shorter cycle length for a standard treatment for refractory metastatic colorectal cancer.
- The shorter cycle was noninferior to the typical longer cycle for overall survival (OS).
- The shorter cycle also limited toxicity.
Why it matters
For patients with refractory metastatic colorectal cancer, a shorter cycle may keep survival comparable while causing less toxicity, which could inform how the regimen is scheduled.
Who’s affected
- oncologists treating colorectal cancer
- patients with refractory metastatic colorectal cancer
- #colorectal cancer
- #oncology
- #clinical trial
- #chemotherapy scheduling
- #toxicity
(MedPage Today) -- A shorter cycle length for a standard treatment for refractory metastatic colorectal cancer was noninferior to the typical longer length for overall survival (OS), while limiting toxicity, the phase III PRABITAS trial from Japan...